Trehalose Designated Orphan Drug for ALS
SLS-005 contains the active ingredient trehalose, a low molecular weight disaccharide that crosses the blood brain barrier, stabilizes proteins and activates autophagy.
SLS-005 contains the active ingredient trehalose, a low molecular weight disaccharide that crosses the blood brain barrier, stabilizes proteins and activates autophagy.
The FDA has granted Fast Track designation to arimoclomol (Orphazyme A/S) for the treatment of amyotrophic lateral sclerosis.
A diagnosis of amyotrophic lateral sclerosis can be overlooked by clinicians unfamiliar with the various signs of the disease.
The FDA has granted Orphan Drug designation to reldesemtiv (Cytokinetics) for the treatment of amyotrophic lateral sclerosis.
The FDA has approved the supplemental New Drug Application for riluzole oral suspension to include administration via percutaneous endoscopic gastrostomy (PEG) tubes for the treatment of ALS.
Mallinckrodt has permanently discontinued the phase 2b PENNANT trial investigating Acthar Gel (repository corticotrophin) for the treatment of amyotrophic lateral sclerosis.
Professional soccer players may have an increased risk for amyotrophic lateral sclerosis.
Tiglutik is supplied as a thickened riluzole liquid that is intended to ease administration for patients with dysphagia.
The FDA approval was supported by data from bioavailability studies comparing riluzole tablets and Tiglutik oral suspension.
Rasagiline was associated with a significant effect on survival within 6 months of treatment in an exploratory analysis.